Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

E.O. Meltzer, P. Kuna, H. Nolte, A. S. Nayak, C. LaForce on Behalf of the P04073 Study Investigators
European Respiratory Journal 2011; DOI: 10.1183/09031936.00020310
E.O. Meltzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: EOMELTZER@aol.com
P. Kuna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Nolte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. S. Nayak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. LaForce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

This study evaluated the effect of mometasone furoate/formoterol (MF/F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function.

This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 years with asthma not well controlled on low-dose inhaled corticosteroids. After a 2–3-week open-label run-in (MF 100 μg twice-daily [b.i.d.]), 746 subjects were randomised to receive MF/F 100/10 μg, MF 100 μg, F 10 μg, or placebo b.i.d. Coprimary endpoints were time-to-first asthma deterioration (MF/F versus F to assess MF's effect) and change in FEV1 AUC0–12h (baseline−week 12; MF/F versus MF to assess F's effect).

The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time-to-first asthma deterioration (p<0.001). Asthma deterioration incidence was also reduced with MF/F versus MF (p=0.006). The therapeutic effect of F in the combination was demonstrated by MF/F versus MF in FEV1 AUC0–12h change (4.00 vs 2.53 L×h, respectively; p=0.001). MF/F treatment also resulted in a marked improvement in health-related quality of life.

MF/F 100/10 μg b.i.d. treatment showed greater clinical efficacy than its individual components or placebo; both components contributed to the efficacy of MF/F.

  • Asthma control
  • asthma deterioration
  • asthma exacerbation
  • efficacy
  • mometasone furoate/formoterol combination therapy
  • randomised clinical trial
  • ERS
Next
Back to top
Vol 59 Issue 5 Table of Contents
European Respiratory Journal: 59 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function
E.O. Meltzer, P. Kuna, H. Nolte, A. S. Nayak, C. LaForce
European Respiratory Journal Jan 2011, erj00203-2010; DOI: 10.1183/09031936.00020310

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function
E.O. Meltzer, P. Kuna, H. Nolte, A. S. Nayak, C. LaForce
European Respiratory Journal Jan 2011, erj00203-2010; DOI: 10.1183/09031936.00020310
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Umeclidinium in patients with COPD
  • EBUS-guided cryobiopsies in peripheral pulmonary lesions
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society